Results

A␤ Clearance Reverses Tau Aggregates
Because the 3xTg-AD mice develop both hallmark Clearance of Intracellular and Extracellular A␤ lesions of AD neuropathology and because anti-A␤ Antibodies against A␤ were administered by intrahippoantibody treatment effectively clears extracellular and campal injections into hemizygous and homozygous intracellular A␤ deposits, we assessed whether adminis3xTg-AD mice (Table 1 ). The 3xTg-AD mice develop both tration of an anti-tau antibody could reduce the tau burplaques and tangles in an age-progressive and regionden in the CA1 pyramidal neurons of the hippocampus. specific manner that closely mimics the hierarchical We found that the tau pathology was unaffected followpattern observed in human AD (Oddo et al., 2003b) . The ing intrahippocampal administration of the anti-tau mononeuropathology that develops in the hemizygous and clonal antibody HT7, which recognizes all isoforms of homozygous 3xTg-AD mice is indistinguishable, alhuman tau (Figures 2A, 2B , and 2I). Recall that the HT7 though the onset is slower in the hemizygous group antibody treatment had no effect on the A␤ pathology (Oddo et al., 2003a) . Consequently, the outcome of the ( Figures 2C, 2D , and 2I). Finally, the tau pathology was immune-based treatments can be evaluated in mice with also unaffected by intrahippocampal administration of different degrees of neuropathology, but where the efan anti-protozoan isotype control antibody or by PBS fect of age and genetic background is not a confound- (Figure 3 ). Therefore, tau immunotherapy had no dising variable. cernible effect on the tau pathology. In the first experiment, a single, intrahippocampal inNotably, administration of the anti-A␤ monoclonal anjection of the anti-A␤ monoclonal antibody 1560 or 4G8 tibodies 4G8 or 1560 effectively cleared the early tau was administered to 12-month-old hemizygous 3xTg-pathology in the somatodendritic compartment of neu-AD mice (Figure 1) . 7 days postinjection, there was a rons within the injected hippocampi ( Figures 2E-2H , 2J, marked reduction in extracellular deposits as deterand 2K). No clearance of tau was observed in the contramined by A␤ immunostaining in the ipsilateral hippolateral, uninjected hippocampi ( Figures 2E and 2G ). In campus in mice receiving the A␤ antibody ( Figure 1A) . the A␤-injected hippocampi, tau staining was absent in Moreover, thioflavin-S-positive structures were also diregions immediately surrounding and extending from minished, further demonstrating clearance of extracelluthe injection site, but the effect was not due to damage lar plaques (cf. Figures 1B and 1C) and also establishing to the CA1 neurons from the injection cannula as they that the lack of A␤ detection in the ipsilateral hippocamappeared morphologically unaltered by hematoxylin pus was not due to competition between the injected and eosin staining ( Figures 8A-8C) . In some cases, a antibody and the secondary antibody used during the near total lack of tau immunoreactivity occurred in the immunostaining procedure. Not only were extracellular injected hippocampi, though the contralateral hippo-A␤ deposits reduced, but we also found that the anticampi retained extensive tau pathology. These results body treatment led to a diminution in the number of indicate that the clearance of the tau load from the so-A␤-immunoreactive neurons around the site of injection, matodendritic compartment, indicative of early tau paindicating that intracellular A␤ was also cleared (Figures thology, by the anti-A␤ antibody is a selective process 1D-1G). Clearance of both extracellular and intracellular that neither depends on a generalized IgG response nor A␤ occurred to the same extent using monoclonal antiis a consequence of an intracerebral injection artifact. bodies 4G8 or 1560 ( Figures 2J and 2K ), indicating that Moreover, both antibodies 4G8 and 1560 effectively the effect was not limited to a specific antibody. Finally, cleared the tau pathology, indicating that these results it is important to note that A␤ pathology remained unafare not unique to a specific anti-A␤ antibody. These fected in the contralateral hippocampi ( Figures 1A, 1B Figure 5C ).
These findings indicate that there is a hierarchical pattern to the clearance and reemergence of the A␤ and tau neuropathology following antibody treatment. The A␤ load is reduced prior to the tau burden, and conversely, the A␤ pathology reemerges well in advance of the tau pathology. Further corroborating a hierarchical relationship between A␤ and tau is our previous finding that, despite the equivalent expression levels of the APP cleared by a single A␤ antibody injection in the 12-transgene product are comparable between 6-and 12-month-old homozygous mice ( Figures 6J and 6K ). Folmonth-old homozygous mice, only a small, but significant, reduction in the tau load was observed, likely due lowing intrahippocampal administration of the anti-A␤ antibody in 6-month-old homozygous mice, both A␤ and to the clearance of nonhyperphosphorylated tau (Figures 6A-6G) . Note that the Gallyas silver method reveals tau pathology were cleared (Figure 7) . In contrast, 12-month-old homozygous mice show only a small dethat the tau load is comparable between the ipsi-and contralateral sections, indicating that aggregated tau crease in the tau load ( Figures 6C-6G) . Therefore, we conclude that the removal of pathological tau from the was unaffected by the antibody treatment ( Figures 6E  and 6F) . somatodendritic compartment is critically dependent on its phosphorylation state: hyperphosphorylated tau agTwo factors could account for the differential clearance of tau in the hemizygous versus homozygous mice: gregates appear to be resistant to A␤-mediated clearance. By extension, our results suggest that A␤-based (1) hyperphosphorylation renders the tau aggregates resistant to A␤-mediated removal, or (2) there is a higher immune approaches may effectively clear both A␤ and tau lesions provided that it is administered early during tau load in the homozygous mice, which express twice as much tau transgene compared to the hemizygous the disease course. mice. To distinguish between these possibilities, we administered A␤ antibody into the hippocampus of 6-monthMechanism of Immune-Mediated Clearance of Tau Is Dependent on the Proteasome old homozygous 3xTg-AD mice. At 6 months of age, the homozygous mice do not show evidence of tau hyperWhile novel, the finding that the tau pathology was cleared by antibodies targeted against A␤ raised the phosphorylation (similar to the 12-month-old hemizygous 3xTg-AD mice), yet steady-state levels of the human tau question as to the mechanism underlying this process. To address this issue, we first determined whether the of tau immunoreactivity between the contra-and ipsilateral sides, despite a significant difference for A␤ ( Figure  A␤ antibody treatment affected the steady-state levels of the APP holoprotein in the injected hippocampi. As 9I). Although we cannot exclude that tau may be removed by other mechanisms, we conclude that A␤ intershown in Figures 8D-8G, these results strongly suggest a link between A␤ and tau. These findings also provide strong supporting evidence for the amyloid cascade hypothesis, which stipuof the APP holoprotein. Overall, the finding that intracellular A␤ may be cleared may have important therapeutic lates that A␤ accumulation triggers the onset of AD and that tau hyperphosphorylation, subsequent neurofibrilimplications for the degenerating muscle disorder inclusion body myositis, which is characterized by the occurlary tangle formation, and cell death are downstream consequences of A␤ aggregation (Hardy and Selkoe, rence of intracellular (but not extracellular) A␤ accumulation in affected myofibers (Mendell et al., 1991) The ␥-secretase inhibitor, DAPT, was administered via intrahippocampal injection into 12-month-old hemizygous 3xTg-AD mice (n ϭ 3). Representative microphotographs of the hippocampus/CA1 pyramidal cell layer show that a single administration of DAPT is sufficient to markedly reduce both A␤ and tau pathology.
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